Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 57

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 57
---
 |    $168,000 |     | $218,400 |

(1) Dr. Kurtoglu was appointed to serve as the Company’s Chief Operating Officer on November 13, 2023. On March 28, 2024, Dr. Kurtoglu’s title was changed to Chief Technology Officer.

(2) Dr. Jewell was appointed to serve as the Company’s Chief Scientific Officer on November 13, 2023.

#### Corporate Performance Objectives
For purposes of the 2024 Bonus Plan, the Compensation Committee selected certain pre-specified advancements to developing our candidate pipeline and advancing that pipeline in the clinic, developments in our corporate strategy regarding manufacturing and Merger integration, and financial objectives regarding operation within budget as the corporate performance measures. Each of these corporate performance measures was equally weighted. The Compensation Committee believed these performance measures were appropriate for our business because they provided a balance between moving our product candidates further in the clinic, managing our expenses, attracting and retaining key talent, and maximizing the potential value of our technology, which it believes most directly influences long-term stockholder value. At the same time, the Compensation Committee established target performance levels for each of these measures at levels that it believed to be challenging, but attainable, through the successful execution of our annual operating plan.

### 2024 Performance Results and Bonus Decisions
In December 2024, the Compensation Committee determined that our actual achievement with respect to the corporate performance objectives under the 2024 Bonus Plan was as follows:

| Corporate Performance Measure               |     | 2024 Target Achievement % |
| Pipeline Development                        |     | 130%                      |
| Corporate Strategy and Business Development |     | 130%                      |
| Finance                                     |     | 130%                      |

The corporate performance measures that factored into the Compensation Committee’s determination included: (i) pipeline development goals, including advancing our clinical programs for Descartes-08 in MG, Descartes-08 in systemic lupus erythematosus, and Descartes-15; (ii) corporate strategy including considerations on manufacturing, successful Merger integration, and strengthening the Company’s position and reputation among the investment community; and (iii) financial goals, including operating within budget.

The Compensation Committee determined that, based on our actual performance with respect to each corporate performance measure, the corporate performance objectives had been achieved, in the aggregate, at a 130% level. Based on its review of our overall corporate performance, the Compensation Committee approved bonus payments as follows for